融合蛋白技术在长效药物开发中的应用  

Application of Fusion Protein Technique in Development of Long-acting Drugs

作　　者：张瑜[1] 赵述强[1] 姚文兵[1] 

机构地区：[1]中国药科大学生命科学与技术学院,江苏南京210009

出　　处：《药学进展》2013年第9期454-459,共6页Progress in Pharmaceutical Sciences

基　　金：江苏省"青蓝工程"资助项目

摘　　要：随着生物技术与制药工业的迅猛发展,越来越多的蛋白和多肽类药物被研发并应用于临床,然而,大多数此类药物普遍存在体内半衰期短的问题,使其应用受到了限制,而融合蛋白技术是目前延长蛋白和多肽类药物半衰期的有效手段之一。对融合蛋白技术在长效药物开发中的应用进行综述,详细介绍该技术的常用融合伴侣、长效机制和相关药物的研发进展,旨在为长效蛋白或多肽类药物的开发提供参考。With the rapid development of biotechnology and pharmaceutical industry, a growing num- ber of protein and polypeptide drugs have been developed and applied in clinic. However, most of the pro- tein and polypeptide drugs exhibit a short plasma half-life, which has limited their use. The fusion protein technique is one of the most effective approaches to extend the half-life of protein and polypeptide drugs. The application of fusion protein technique in development of long-acting drugs has been reviewed in this paper. The commonly used chaperones and long-acting mechanisms of the fusion proteins, as well as re- search progresses of the related drugs have been also introduced in detail, in order to provide references for the development of long-acting protein and polypeptide drugs.

关 键 词：融合蛋白 半衰期 Fc片段 人血清白蛋白 转铁蛋白 

分 类 号：TQ460.1[化学工程—制药化工]